Share via e-mail

Aveo Oncology has submitted a new drug application to the Food and Drug Administration for a potential treatment for advanced kidney cancer. The Cambridge company has a deal with Japanese drug maker Astellas Pharma Inc. to commercialize tivozanib in some other countries. The application asks the FDA for approval to market tivozanib in the United States for patients with advanced renal cell carcinoma. An estimated 250,000 people are diagnosed with kidney cancer annually.

BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.

Thanks & Welcome to Globe.com

You now have unlimited access for the next two weeks.

BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.